Pharma BD Deal Intelligence
Relay Therapeutics / Pfizer Inc.
2024 · Co-Development · Complete
Relay Therapeutics and Pfizer entered a clinical trial collaboration to evaluate Pfizer's atirmociclib in combination with Relay's RLY-2608 and fulvestrant in patients with PI3K-alpha-mutated HR+/HER2- metastatic breast cancer, with trial initiation planned by end of 2024. Pfizer supplies atirmociclib and Relay conducts the study; no financial terms were disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jun 05, 2024
- Deal type Co-Development
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2024 deals